Post by Mirum Pharmaceuticals, Inc.

For people living with fibrodysplasia ossificans progressiva (FOP), every step toward progress matters. Together with our partner Incyte, we are pleased that late-breaking results from the pivotal PROGRESS study evaluating an investigational ALK2 inhibitor have been accepted for presentation at ENDO 2026. We remain focused on moving with urgency on behalf of the FOP community.